Dronabinol for Pain and Inflammation in Adults Living with Sickle Cell Disease
Other Hematopoietic | Sickle Cell Disorders
What is the purpose of this trial?
This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
- Trial withYale Cancer Center
- Start Date07/02/2019
- End Date06/30/2020
- Last Updated08/06/2019
- Study HIC#2000021179